AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

Modularly engineered prodrug-nanoassemblies for cancer therapy: Nonpharmacological moiety dominating delivery fates

Yuequan Wang1Qian Qiu1Rui Liao1Xinhui Wang1Ziran Zhou1Xuanbo Zhang1Haotian Zhang2Zhonggui He1Shenwu Zhang1( )Cong Luo1 ( )Jin Sun1 ( )
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
Show Author Information

Abstract

Self-engineered small-molecule prodrug-nanoassemblies have emerged as promising nanomedicines for cancer treatment. Modular design of prodrug molecules is crucial to guarantee the favorable assembly stability, tumor-specific prodrug activation, and satisfactory antitumor effect. However, too much attention has been paid to the pharmacophores and chemical linkages in prodrug molecules while neglects the vital roles of nonpharmacological moieties. Herein, we found that iso-carbon fatty acids with different number, position, and cis-trans configuration of double bonds dramatically affect the nanoassembly feature and drug delivery fates of thioether-linked paclitaxel prodrug-nanoassemblies. Particularly, the number and cis-trans configuration of double bonds in fatty acid moieties not only dominate the self-assembly ability and colloidal stability of prodrugs, but also exert significant influences on the pharmacokinetics, prodrug activation, and antitumor activity of prodrug-nanoassemblies. Finally, oleic acid with one cis double bond stands out as the optimal nonpharmacological moiety for thioether-linked paclitaxel prodrug-nanoassemblies. This study elucidates the crucial roles of nonpharmacological moieties in prodrugs, and provides new insights into the modular design of prodrug-based nanomedicines for cancer therapy.

Graphical Abstract

Modularly engineered prodrug-nanoassemblies were successfully prepared for cancer therapy.

Electronic Supplementary Material

Download File(s)
12274_2022_4819_MOESM1_ESM.pdf (2.9 MB)
12274_2022_4819_MOESM2_ESM.pdf (6.5 MB)

References

【1】
【1】
 
 
Nano Research
Pages 980-990

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Wang Y, Qiu Q, Liao R, et al. Modularly engineered prodrug-nanoassemblies for cancer therapy: Nonpharmacological moiety dominating delivery fates. Nano Research, 2023, 16(1): 980-990. https://doi.org/10.1007/s12274-022-4819-z
Topics:

1627

Views

13

Crossref

13

Web of Science

14

Scopus

0

CSCD

Received: 28 June 2022
Revised: 20 July 2022
Accepted: 25 July 2022
Published: 26 August 2022
© Tsinghua University Press 2022